Because individuals with deficient as well as intermediate levels of G6PD activity are at risk of developing adverse effects when receiving radical treatment for malaria, the WHO recommends G6PD testing before prescribing 8-aminoquinolines. This evidence concerns the gene G6PD and malaria.